學習和工作經曆

1983-1987  學士(化學)，浙江師範大學。

1987-1990  碩士(有機化學)，中國科學院上海藥物研究所。

1994-1999  博士(藥物化學)，美國田納西大學。

1999-2002  博士後(生物化學，特别是酶學)，美國約翰霍普金斯大學醫學院。

2002-2004  研究助理(Research Associate)(生物化學，特别是酶學)，美國約翰霍普金斯大學醫學院。

2004-2011  助理教授(The James L.and Martha J.Foght Assistant Professor,tenure-track)，美國Akron大學化學系。

2007-2011  兼職助理教授，美國Akron大學綜合生物科學博士點(Integrated Bioscience Ph.D. Program)

2012-至今    教授，世界杯正规买球app

主要榮譽和獎勵

2009 應邀主持“酶，輔酶，代謝途徑”Gordon研究大會中的“染色質重造及轉錄”會議

2012 入選2012年度江蘇特聘教授。

2012 入選2012年度江蘇省“雙創計劃”。

研究興趣

藥物化學：發展催化機制導向的(catalytic mechanism-based)酶抑制劑；發展酶催化反應的化學探針(activity-based chemical probe)并探索其在生物學和藥物化學研究中的應用；新型肽裝訂(peptide stapling)途徑的發展并探索其在藥物化學研究中的應用。

本着這些研究興趣，本課題組在美國Akron大學期間首次在世界範圍内開展了發展催化機制導向的蛋白酰化賴氨酸去酰化酶sirtuin抑制劑的工作，并且發展出了三大主類催化機制導向的sirtuin抑制彈頭(即硫酰胺類(thioacyl-type)，硫脲類(thiourea-type)，酰胺類(carboxamide-type))的原型，而且最近幾年發展出了迄今最為強效和/或選擇性并且酶解穩定及能透過細胞膜的sirtuin抑制劑 (參見：Jiang, Yanhong; Liu, Jiajia; Chen, Di; Yan, Lingling; Zheng, Weiping*. Sirtuin inhibition: strategies, inhibitors, and therapeutic potential. Trends in Pharmacological Sciences 2017, 38, 459-472)。迄今的研究表明該催化機制導向的設計途徑代表目前最為簡便但是最為有效的sirtuin抑制劑先導化合物産生 (Lead Generation) 的方法。本課題組在sirtuin的化學生物學、生物有機化學、藥物化學領域已經建立了國際學術地位 (參見：我應邀為世界著名出版集團Elsevier的系列叢書Progress in Molecular Biology and Translational Science主編了題為“Sirtuins in Health and Disease”的專著 (https://www.sciencedirect.com/science/bookseries/18771173，2018年2月出版))。

本課題組近年與美國Case Western Reserve大學Zhenghe Wang教授課題組合作成功地鑒定出一個新型的隻存在于某些結腸癌細胞内的基于蛋白-蛋白相互作用 (protein-protein interaction, PPI) 的癌症藥物靶點 (參見：Hao, Yujun; Wang, Chao; Cao, Bo; Hirsch, Brett M.; Song, Jing; Markowitz, Sanford D.; Ewing, Rob M.; Sedwick, David; Liu, Lili; Zheng, Weiping*; Wang, Zhenghe*. Gain of interaction with IRS1 by p110alpha helical domain mutants is crucial for their oncogenic functions. Cancer Cell 2013, 23, 583-593；評論文章：John E. Burke and Roger L. Williams (MRC Laboratory of Molecular Biology, Cambridge, UK). Connecting with an old partner in a new way. Cancer Cell 2013, 23, 559-561)。雖然在這項研究中運用已知的全碳氫鍊肽裝訂(all-hydrocarbon peptide stapling)途徑發展出了一個強效且能透過細胞膜的該PPI的抑制劑，我們有興趣發展新型且更優越的肽裝訂途徑以運用到這項研究中以及整個藥物化學的範疇中。

本課題組的研究對于發展新型的藥物 (特别是抗癌藥物) 具有深遠的意義。參與本課題組的研究可以得到現代藥物化學科研理念上的熏陶以及科研技術上的裝備。

代表性學術論文(*表示為通訊作者)

1. Wu, Bo; Zheng, Weiping*. Bis-lactam peptide [i, i+4]-stapling with a-methylated thialysines. Molecules 2020, 25, 4506.

2. Li, Renwu; Yan, Lingling; Sun, Xun*; Zheng, Weiping*. A bicyclic pentapeptide-based highly potent and selective pan-SIRT1/2/3 inhibitor harboring N^e-thioacetyl-lysine. Bioorganic & Medicinal Chemistry 2020, 28, 115356.

3. Jiang, Yanhong; Zheng, Weiping*. Cyclic tripeptide-based potent and selective human SIRT5 inhibitors. Medicinal Chemistry 2020, 16, 358-367.

4. Li, Shengchao; Wu, Bo; Zheng, Weiping*. Cyclic tripeptide-based potent human SIRT7 inhibitors. Bioorganic & Medicinal Chemistry Letters 2019, 29, 461-465.

5. Hu, Xiao; Wu, Bo; Zheng, Weiping*. Bis-lactam peptide [i, i+4]-stapling. Chinese Journal of Chemistry 2019, 37, 244-248.

6. Hu, Xiao; Zheng, Weiping*. Chemical probes in sirtuin research. In Progress in Molecular Biology and Translational Science, 2018, Volume 154 (Sirtuins in Health and Disease, Edited by Weiping Zheng), Pages 1-24.

7. Li, Shengchao; Zheng, Weiping*. Mammalian sirtuins SIRT4 and SIRT7. In Progress in Molecular Biology and Translational Science, 2018, Volume 154 (Sirtuins in Health and Disease, Edited by Weiping Zheng), Pages 147-168.

8. Hu, Xiao; He, Yanhua; Wu, Liping; Hao, Yujun; Wang, Zhenghe; Zheng, Weiping*. Novel all-hydrocarbon stapled p110alpha[E545K] peptides as blockers of the oncogenic p110alpha[E545K]-IRS1 interaction. Bioorganic & Medicinal Chemistry Letters 2017, 27, 5446-5449.

9. Mukhtar, Yusif M.; Huang, Yajun; Liu, Jiajia; Chen, Di; Zheng, Weiping*. Acetanilide and bromoacetyl-lysine derivatives as activators for human histone deacetylase 8. Bioorganic & Medicinal Chemistry Letters 2017, 27, 2319-2323.

10. Jiang, Yanhong; Liu, Jiajia; Chen, Di; Yan, Lingling; Zheng, Weiping*. Sirtuin inhibition: strategies, inhibitors, and therapeutic potential. Trends in Pharmacological Sciences 2017, 38, 459-472. (Invited)

11. Wang, Juan; Zang, Wenwen; Liu, Jiajia; Zheng, Weiping*. Bivalent SIRT1 inhibitors. Bioorganic & Medicinal Chemistry Letters 2017, 27, 180-186.

12. Chen, Di; Zheng, Weiping*. Cyclic peptide-based potent and selective SIRT1/2 dual inhibitors harboring N(epsilon)-thioacetyl-lysine. Bioorganic & Medicinal Chemistry Letters 2016, 26, 5234-5239.

13. Liu, Jiajia; Huang, Yajun; Zheng, Weiping*. A selective cyclic peptidic human SIRT5 inhibitor. Molecules 2016, 21, 1217.

14. Liu, Jiajia; Zheng, Weiping*. Cyclic peptide-based potent human SIRT6 inhibitors. Organic & Biomolecular Chemistry 2016, 14, 5928-5935.

15. Huang, Yajun; Liu, Jiajia; Yan, Lingling; Zheng Weiping*. Simple N(epsilon)-thioacetyl- lysine-containing cyclic peptides exhibiting highly potent sirtuin inhibition. Bioorganic & Medicinal Chemistry Letters 2016, 26, 1612-1617.

16. He, Yanhua; Yan, Lingling; Zang, Wenwen; Zheng, Weiping*. Novel sirtuin inhibitory warheads derived from the N(epsilon)-acetyl-lysine analog L-2-amino-7-carboxamidoheptanoic acid. Organic & Biomolecular Chemistry 2015, 13, 10442-10450.

17. Chen, Bing; Wang, Juan; Huang, Yajun; Zheng, Weiping*. Human SIRT3 tripeptidic inhibitors containing N(epsilon)-thioacetyl-lysine. Bioorganic & Medicinal Chemistry Letters 2015, 25, 3481-3487.

18. Zang, Wenwen; Hao, Yujun; Wang, Zhenghe; Zheng, Weiping*. Novel thiourea-based sirtuin inhibitory warheads. Bioorganic & Medicinal Chemistry Letters 2015, 25, 3319-3324.

19. Chen, Bing; Zang, Wenwen; Wang, Juan; Huang, Yajun; He, Yanhua; Yan, Lingling; Liu, Jiajia; Zheng, Weiping*. The chemical biology of sirtuins. Chemical Society Reviews 2015, 44, 5246-5264. (Invited)

20. He, Yanhua; Chen, Di; Zheng, Weiping*. An enhanced functional interrogation/ manipulation of intracellular signaling pathways with the peptide “stapling” technology. Oncogene 2015, 34, 5685-5698. (Invited)

21. Zheng, Weiping*; Huang, Yajun. The chemistry and biology of the alpha-ketoglutarate- dependent histone N(epsilon)-methyl-lysine demethylases. MedChemComm 2014, 5, 297-313. (Invited for the themed issue on Chemical Biology for Target Identification and Validation, guest edited by Prof. Nathanael Gray (Harvard University, U.S.A.) and Dr. Lyn Jones (Pfizer, Cambridge, U.S.A.).

22. Zheng, Weiping*. Sirtuins as emerging anti-parasitic targets. European Journal of Medicinal Chemistry 2013, 59, 132-140. (Invited)

23. Hao, Yujun; Wang, Chao; Cao, Bo; Hirsch, Brett M.; Song, Jing; Markowitz, Sanford D.; Ewing, Rob M.; Sedwick, David; Liu, Lili; Zheng, Weiping*; Wang, Zhenghe*. Gain of interaction with IRS1 by p110alpha helical domain mutants is crucial for their oncogenic functions. Cancer Cell 2013, 23, 583-593. (Comment by John E. Burke and Roger L. Williams (MRC Laboratory of Molecular Biology, Cambridge, UK) in: Connecting with an old partner in a new way. Cancer Cell 2013, 23, 559-561)

24. Hirsch, Brett M.; Hao, Yujun; Li, Xiaopeng; Wesdemiotis, Chrys; Wang, Zhenghe; Zheng, Weiping*. A mechanism-based potent sirtuin inhibitor containing N(epsilon)-thiocarbamoyl-lysine (TuAcK). Bioorganic & Medicinal Chemistry Letters 2011, 21, 4753-4757.

25. Hirsch, Brett M.; Du, Zhanwen; Li, Xiaopeng; Sylvester, Jorge A.; Wesdemiotis, Chrys; Wang, Zhenghe; Zheng, Weiping*. Potent sirtuin inhibition bestowed by L-2-amino-7-carboxamidoheptanoic acid (L-ACAH), a N(epsilon)-acetyl-lysine analog. MedChemComm 2011, 2, 291-299.

26. Fatkins, David G.; Monnot, Andrew D.; Zheng, Weiping*. N(epsilon)-thioacetyl-lysine: a multi-facet functional probe for enzymatic protein lysine N(epsilon)-deacetylation. Bioorganic & Medicinal Chemistry Letters 2006, 16, 3651-3656.